All articles by Mekala ShivaramPrasad

  1. AbbVie’s glioblastoma multiforme therapy receives orphan drug designation

    AbbVie has obtained orphan drug designation from the European Medicines Agency (EMA) and the US FDA for its anti-epidermal growth…
    Read More…

    5 Aug
  2. Alexion receives orphan drug designation for Soliris in Europe

    The European Commission has granted orphan drug designation to Alexion Pharmaceuticals’ Soliris (eculizumab), a terminal complement inhibitor, to treat patients…
    Read More…

    4 Aug
  3. Bristol-Myers Squibb and Allied Minds form new research enterprise

    Bristol-Myers Squibb and Allied Minds have formed a new jointly owned enterprise, Allied-Bristol Life Sciences, aimed at advancing discoveries of…
    Read More…

    4 Aug
  4. FDA approves Jardiance tablets for type 2 diabetes

    The US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) tablets, developed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly…
    Read More…

    3 Aug
  5. Vertex obtains receives European approval for cystic fibrosis oral medicine

    The European Commission has approved Vertex Pharmaceuticals’ oral medicine Kalydeco (ivacaftor) for people with cystic fibrosis (CF). Kalydeco is for…
    Read More…

    3 Aug
  6. Pfizer to acquire Baxter’s portfolio of marketed vaccines for $635m

    Pfizer and Baxter have entered into a definitive agreement under which Pfizer will acquire Baxter’s portfolio of marketed vaccines for…
    Read More…

    31 Jul
  7. Meda agrees to acquire Rottapharm for €2.3bn

    Swedish drugmaker Meda has agreed to acquire Italy-based Rottapharm Madaus for around €2.3bn as part of its strategy to boost…
    Read More…

    31 Jul
  8. FDA approves Bayer’s Eylea to treat diabetic macular edema

    Bayer has announced the US Food and Drug Administration’s (FDA) approval of Eylea, an aflibercept solution for injection into the…
    Read More…

    30 Jul
  9. AstraZeneca to have rights of Almirall’s respiratory franchise

    Spain-based Almirall and AstraZeneca have entered into an agreement, involving Almirall transfering the rights to its respiratory franchise to Astrazeneca…
    Read More…

    30 Jul
  10. EMA committee recommends approval of Gilead Sciences’ Zydelig

    The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Gilead…
    Read More…

    29 Jul
Close
Close
Close

Go Top